- Poster presentation
- Open Access
IL-1 receptor antagonist restores IL-18 NK cell axis in systemic JIA
© Vastert et al; licensee BioMed Central Ltd. 2012
- Published: 28 November 2012
- Line Treatment
- Inflammasome Activation
- Cell Axis
- Systemic Onset Juvenile Idiopathic Arthritis
Systemic onset juvenile idiopathic arthritis (SoJIA) is an acquired auto-inflammatory disease characterized by systemic inflammation and innate immune activation reflected by uncontrolled production of cytokines such as IL-1, IL- 6 and IL-18. In SoJIA, NK cell function is severely hampered despite high levels of IL-18.
We recently found that defective phosphorylation of the IL-18 receptor beta is responsible for the deficient IL-18-NK cell axis in SoJIA.
To study first line treatment with recombinant IL-1 receptor antagonist (rIL-1RA, Anakinra) in 16 newly diagnosed and steroid naïve systemic onset JIA patients.
Clinical outcome was measured using ACRp70 and ACRp90. Furthermore, NK cell lytic function, inflammasome activity and cytokine levels in plasma were assessed during follow up (max 3 years).
Here we show that patients with SoJIA have increased inflammasome activation leading to elevated IL-18 levels. First line treatment in steroid naïve patients, with rIL-1RA effectively down-regulated IL-18 levels through suppression of inflammasome activation and led to rapid resolution of clinical features in 87% (ACRp90) of patients. Furthermore, using rIL-1RA as first line treatment approach the defective IL-18-NK cell axis is restored as shown by improved lytic NK cell function and regaining of the NK cell responsiveness to IL-18 stimulation.
These data suggest that the mechanisms of inflammatory control induced by rIL-1RA in SoJIA patients involves more than blocking IL-1R. Our data show that rIL-1RA directly targets the inflammasome and restores the IL-18 NK cell axis as well.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.